Core Insights - 10x Genomics is acquiring Scale Biosciences for $30 million in stock and cash, aiming to enhance its single-cell analysis capabilities [1][2] - The acquisition will integrate Scale's indexing and quantum barcode technologies into 10x Genomics' Chromium platform, making single-cell analysis more accessible and cost-effective for researchers [2] Financial Performance - In Q2, 10x Genomics reported total revenue of $173 million, up from $153 million year-over-year; however, core revenue decreased by 5% to $146 million after excluding a $27.3 million settlement related to a patent lawsuit [3] - Instrument revenue fell by 39% to $14.5 million, while consumables revenue slightly decreased by 1% to $122 million; spatial instrument revenue dropped by 42% to $8.8 million, but spatial consumables revenue increased by 34% to $36.4 million [3] - The company achieved a net profit of $34.5 million, or $0.28 per share, compared to a loss of $37.9 million, or $0.32 per share, in the same quarter last year [5] Regional Revenue Breakdown - Revenue from the Americas totaled $106 million, a 14% increase from $93.1 million year-over-year; EMEA revenue was $34.7 million, down 7% from $37.4 million; APAC revenue rose by 41% to $32 million from $22.7 million [4] Future Guidance - 10x Genomics expects Q3 revenue to be between $140 million and $144 million, which includes approximately $4 million in revenue from customers in China who advanced purchases due to anticipated tariff changes [6]